Prof. Jie He 赫捷
Oncology
Cancer Hospital, Chinese Academy of Medical Sciences (National Cancer Center), Beijing
Public profile Compiled from public sources. We do not work directly with this doctor, but we can find a specialist in this field to review your case.
Get a specialist opinionCurrent positions
- Academician, Chinese Academy of Sciences
- Director, National Cancer Center
- President, Cancer Hospital, Chinese Academy of Medical Sciences
Checked against a public report (2026-07). Positions change; the hospital's website is the final word.
Clinical focus: Minimally invasive lung surgery and segmentectomy; radical esophageal cancer surgery with lymph node dissection; surgical treatment of mediastinal tumors; multidisciplinary care for thoracic tumors; early lung cancer screening and diagnosis.
Conditions and procedures: Lung cancer, Esophageal cancer, Mediastinal tumors, Thoracic tumors
Compiled from public information; not confirmed with the hospital or the doctor.
Name order: in Chinese the family name comes first (He Jie). Papers usually list the name as Jie He.
Selected publications
145 first- or senior-author papers on PubMed where the author's own affiliation is this hospital (145 since 2016), counted among the 200 most recent matching papers. Most recent:
- Cancer Lett, 2026 (senior author): KEAP1 loss-of-function suppresses immunogenic ferroptosis and limits PD-1 blockade efficacy through an NRF2-FSP1 pathway. PubMed 42753906
- J Natl Cancer Cent, 2026 (senior author): Premature cancer mortality in China based on cancer registry. PubMed 42984710
- J Natl Cancer Cent, 2026 (senior author): Cancer incidence and mortality in China, 2024. PubMed 42984702
- Cancer Lett, 2026 (senior author): RAD21 drives tumor progression and confers anti-PD-1 resistance by reprogramming tumor-associated macrophages via upregulation of CSF1 signaling. PubMed 42140344
- Sci China Life Sci, 2026 (senior author): Efficacy of immune checkpoint inhibitors in female patients with cancer: a systematic review and meta-analysis. PubMed 42752777
- CA Cancer J Clin, 2026 (senior author): Early stage nonsmall cell lung cancer: Toward a risk-adaptive paradigm in the era of biologic precision. PubMed 42713910
- Gut, 2026 (senior author): Proteomic landscape of pan-tissue neuroendocrine carcinomas defines subtype-specific functional architectures, biomarkers and therapeutic targets. PubMed 42648907
- Cancer Lett, 2026 (senior author): GAB3 suppresses lung adenocarcinoma progression by inhibiting the MAPK signaling and potentiating CD8+ T cell immunity. PubMed 42031161
Each paper was checked automatically: the author listed with this name must give this hospital as their affiliation; because this name is common, the affiliation must also name the specialty. See the full PubMed search.
This profile has not been reviewed by the doctor. How we build this directory.
Want a specialist to review your case?
Send your records. We find a specialist in this field who can review your case and recommend a treatment plan.
Get a specialist opinion